"We are extremely disappointed for the Duchenne community and strongly disagree with the agency's conclusions," said Stuart W. Peltz, Ph.D., chief executive officer of PTC Therapeutics. "We believe that this decision fails to consider the benefit-risk of ataluren and the high unmet medical need. Therefore, we plan to file a formal dispute resolution request next week."

目前还没消息吧